Free Trial
NASDAQ:DNTH

Dianthus Therapeutics Q3 2024 Earnings Report

Dianthus Therapeutics logo
$24.81 +0.57 (+2.35%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$24.93 +0.12 (+0.48%)
As of 09:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dianthus Therapeutics EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.59
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Dianthus Therapeutics Revenue Results

Actual Revenue
$2.17 million
Expected Revenue
$1.07 million
Beat/Miss
Beat by +$1.10 million
YoY Revenue Growth
N/A

Dianthus Therapeutics Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Dianthus Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Dianthus Therapeutics Earnings Headlines

Wedbush Forecasts Reduced Earnings for Dianthus Therapeutics
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Dianthus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email.

About Dianthus Therapeutics

Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

View Dianthus Therapeutics Profile

More Earnings Resources from MarketBeat